Literatür Detay Bilgisi
Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy;

Yazarlar : Evelyn E, Joelle H, Liying Z et al

Yayın : Radiother Oncol

Yayın Yılı : 2014

Pubmed Linki :

Konu : Radyasyon Onkolojisi

Literatür İçeriği :  BACKGROUND AND PURPOSE Initial results of Stereotactic Ablative Body Radiotherapy (SABR) in the treatment of localized prostate cancer appear promising however long-term quality of life (QOL) outcomes and dosimetric correlates are necessary.

MATERIAL AND METHODS A phase I/II study was performed where low risk prostate cancer patients received SABR 35Gy in 5 fractions, once weekly. Patient self-reported QOL was measured using the Expanded Prostate Cancer Index Composite (EPIC) at baseline and q6month up to 5years. Urinary, bowel and sexual domains were analyzed. A minimally clinical important change (MCIC) was defined as 0.5∗standard deviation of the baseline. Univariate and multivariate logistic regression were used to identify dosimetric predictors of MCIC.

RESULTS 84 patients were included. The median follow-up was 50.8months (interquartile range [IQR], 44.7-56.3). 17.9%, 26.2% and 37.5% of patients reported worse QOL on follow up in the urinary, bowel and sexual domains respectively. On univariate analysis Rectal V31.8>10%, D1cc>35Gy were associated with bowel MCIC, penile bulb (PB) V35>4%, V20>40% with sexual MCIC. Of these factors only rectal D1cc and PB V35 were predictors of worse QOL on multivariate analysis.

CONCLUSIONS Long-term single-institution QOL outcomes are encouraging. Rigorous dosimetric constraints are needed to keep bothersome side effects low.

Literatür Arşivi

Konusu Aynı Olan Diğer Materyaller
SunumlarVideolarOlgu Tartışması